Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 312
Selected: 0
NCT IDTitle
NCT01522170aHUS Observational Long Term Follow-Up
NCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
NCT04581785Gene Therapy With hLB-001 in Pediatric Patients With Severe Methylmalonic Acidemia
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT04573309Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
NCT07218887ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy
NCT00034359Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
NCT00727194Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
NCT04564339Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT00744042Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
NCT01229254Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter
NCT01194804E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
NCT02220725A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
NCT03555539Study of Danicopan in Participants With Hepatic Impairment
NCT06160414A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants
NCT00122304Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
NCT04526197Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
NCT01716728Identification of Undiagnosed Lysosomal Acid Lipase Deficiency
NCT01412047Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study
NCT02496689Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
NCT05097989Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT04304144A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
NCT04202341Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
NCT03218241Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote
NCT05840055ACT with NMOSD Patients and Caregivers Pilot Study
NCT02301624Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis
NCT06967480Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis
NCT01275287Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
NCT04757259Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
NCT07413679Long-term Safety of Danicopan: IPIG Registry-based Cohort Study
NCT06079281Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
NCT01205152Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
NCT05047458A Study of Single-dose ALXN2050 in Healthy Adults
NCT04623710Study of ALXN2050 in Participants With Renal Impairment
NCT00838513Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
NCT05506254Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
NCT02112994Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency
NCT06449001Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
NCT04889677Study of a Single Dose of Danicopan in Healthy Participants
NCT04889391Study of Radiolabeled Danicopan in Healthy Male Participants
NCT02345421A Study to Identify and Characterize LAL-D Patients in High-risk Populations
NCT04189315Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease
NCT03574506Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series
NCT04743804Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
NCT07024563Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT05683678US Selumetinib Registry
NCT05288816A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
NCT06830798Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT05234567A Prospective Sub-Study of the Global Hypophosphatasia Registry
NCT03330457A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing